These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

301 related articles for article (PubMed ID: 17413003)

  • 1. Cancer immunologists and cancer biologists: why we didn't talk then but need to now.
    Prendergast GC; Jaffee EM
    Cancer Res; 2007 Apr; 67(8):3500-4. PubMed ID: 17413003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immune response and cancer].
    El Hage F; Abouzahr-Rifai S; Meslin F; Mami-Chouaib F; Chouaib S
    Bull Cancer; 2008 Jan; 95(1):57-67. PubMed ID: 18230571
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell intrinsic mechanisms of T-cell inhibition and application to cancer therapy.
    Peggs KS; Quezada SA; Allison JP
    Immunol Rev; 2008 Aug; 224():141-65. PubMed ID: 18759925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications.
    Sigalotti L; Fratta E; Coral S; Cortini E; Covre A; Nicolay HJ; Anzalone L; Pezzani L; Di Giacomo AM; Fonsatti E; Colizzi F; Altomonte M; Calabrò L; Maio M
    J Cell Physiol; 2007 Aug; 212(2):330-44. PubMed ID: 17458893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The promise of 4-1BB (CD137)-mediated immunomodulation and the immunotherapy of cancer.
    Lynch DH
    Immunol Rev; 2008 Apr; 222():277-86. PubMed ID: 18364008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer immunotherapy.
    Baxevanis CN; Perez SA; Papamichail M
    Crit Rev Clin Lab Sci; 2009; 46(4):167-89. PubMed ID: 19650714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour escape mechanisms and their therapeutic implications in combination tumour therapy.
    Bhutia SK; Mallick SK; Maiti TK
    Cell Biol Int; 2010 Apr; 34(5):553-63. PubMed ID: 20384587
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-driven evolution of immunosuppressive networks during malignant progression.
    Kim R; Emi M; Tanabe K; Arihiro K
    Cancer Res; 2006 Jun; 66(11):5527-36. PubMed ID: 16740684
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors.
    Khawli LA; Hu P; Epstein AL
    Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dormant tumor cells as a therapeutic target?
    Quesnel B
    Cancer Lett; 2008 Aug; 267(1):10-7. PubMed ID: 18384938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inflammation: gearing the journey to cancer.
    Kundu JK; Surh YJ
    Mutat Res; 2008; 659(1-2):15-30. PubMed ID: 18485806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NK cell-based cancer immunotherapy.
    Stagg J; Smyth MJ
    Drug News Perspect; 2007 Apr; 20(3):155-63. PubMed ID: 17520092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention.
    Whiteside TL
    Semin Cancer Biol; 2006 Feb; 16(1):3-15. PubMed ID: 16153857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathophysiology of tumor-associated macrophages.
    Yuan A; Chen JJ; Yang PC
    Adv Clin Chem; 2008; 45():199-223. PubMed ID: 18429498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Co-evolution of tumor cells and their microenvironment.
    Polyak K; Haviv I; Campbell IG
    Trends Genet; 2009 Jan; 25(1):30-8. PubMed ID: 19054589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Host response to colorectal cancer.
    Salama P; Platell C
    ANZ J Surg; 2008 Sep; 78(9):745-53. PubMed ID: 18844901
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour-host interactions: implications for developing anti-cancer therapies.
    Gadea BB; Joyce JA
    Expert Rev Mol Med; 2006 Dec; 8(30):1-32. PubMed ID: 17156575
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Capitalizing on the immunogenicity of dying tumor cells.
    Fonseca C; Dranoff G
    Clin Cancer Res; 2008 Mar; 14(6):1603-8. PubMed ID: 18347160
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [From single disseminated tumor cells to metastasis insights from molecular genetic analyses of single cells].
    Klein CA
    Verh Dtsch Ges Pathol; 2003; 87():158-64. PubMed ID: 16888908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor resistance to specific lysis: a major hurdle for successful immunotherapy of cancer.
    Chouaib S; Meslin F; Thiery J; Mami-Chouaib F
    Clin Immunol; 2009 Jan; 130(1):34-40. PubMed ID: 19013109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.